139 related articles for article (PubMed ID: 2942235)
1. Differential androgen modulation of AXC/SSh rat prostate cancer cell proliferation in vitro and its antagonism by antiandrogen.
Huot RI; Shain SA
Cancer Res; 1986 Aug; 46(8):3775-81. PubMed ID: 2942235
[TBL] [Abstract][Full Text] [Related]
2. Proliferation of AXC/SSh rat prostate cancer cells in vitro is androgen modulated.
Shain SA; Huot RI
J Steroid Biochem; 1987; 27(1-3):503-12. PubMed ID: 3320541
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and morphological characterization of clonal AXC rat prostate cancer cells.
Shain SA; Huot RI; Gorelic LS; Smith GC
Cancer Res; 1984 May; 44(5):2033-42. PubMed ID: 6713398
[TBL] [Abstract][Full Text] [Related]
4. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
5. Growth-stimulating effect of pharmacological doses of estrogen on androgen-dependent Shionogi carcinoma 115 in vivo but not in cell culture.
Noguchi S; Nishizawa Y; Nakamura N; Uchida N; Yamaguchi K; Sato B; Kitamura Y; Matsumoto K
Cancer Res; 1987 Jan; 47(1):263-8. PubMed ID: 3791211
[TBL] [Abstract][Full Text] [Related]
6. Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid conjugates on cancer cell proliferation in vitro.
Huot RI; Shain SA
J Steroid Biochem; 1988 Jun; 29(6):617-21. PubMed ID: 2838688
[TBL] [Abstract][Full Text] [Related]
7. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
8. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
9. Negative controls of cell proliferation: human prostate cancer cells and androgens.
Sonnenschein C; Olea N; Pasanen ME; Soto AM
Cancer Res; 1989 Jul; 49(13):3474-81. PubMed ID: 2731169
[TBL] [Abstract][Full Text] [Related]
10. Differences in responsiveness of clonally derived AXC/SSh rat prostate cancer cells to secreted or prototypic mitogens.
Shain SA; Koger JD
Cancer Res; 1989 Jul; 49(14):3898-903. PubMed ID: 2786746
[TBL] [Abstract][Full Text] [Related]
11. The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells.
Lucia MS; Sporn MB; Roberts AB; Stewart LV; Danielpour D
J Cell Physiol; 1998 May; 175(2):184-92. PubMed ID: 9525477
[TBL] [Abstract][Full Text] [Related]
12. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line.
Hofbauer LC; Hicok KC; Khosla S
J Cell Biochem; 1998 Oct; 71(1):96-108. PubMed ID: 9736458
[TBL] [Abstract][Full Text] [Related]
13. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton MA; Shuster TD; Fertig AM; Taplin ME; Kolvenbag G; Bubley GJ; Balk SP
Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
[TBL] [Abstract][Full Text] [Related]
15. The effects of steroid hormones on a human colon cancer cell line in vitro.
Lointier P; Wildrick DM; Boman BM
Anticancer Res; 1992; 12(4):1327-30. PubMed ID: 1503430
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
[TBL] [Abstract][Full Text] [Related]
18. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
Algarté-Génin M; Cussenot O; Costa P
Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
[TBL] [Abstract][Full Text] [Related]
19. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
Shain SA
Mol Urol; 2001; 5(3):121-30. PubMed ID: 11690559
[TBL] [Abstract][Full Text] [Related]
20. Effects of androgens, progesterone and their antagonists on the developmental competence of in vitro matured bovine oocytes.
Silva CC; Knight PG
J Reprod Fertil; 2000 Jul; 119(2):261-9. PubMed ID: 10864838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
